Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Or leave a message with a formal purchase order (PO) Or credit card.
Recombinant SARS-CoV-2 Spike RBD
Recombinant SARS-CoV-2 spike RBD-Fc, biotinylated His-tag and Fc-fused spike RBD, spike RBD antibody and immunoassay kits, custom antibody and kit development services are available.
BP003052: Recombinant SARS-CoV-2 Spike RBD-His-Avi
Source: Recombinant SARS-CoV-2 Spike RBD (Arg319-Asn532) was expressed in mammalian cells with a His tag and Avi at the C-terminus.
Predicted molecular mass: 27 kDa. Due to glycosylation, the recombinant SARS-CoV-2 Spike RBD migrates to 36-40 kDa based on the Bis-Tris PAGE result.
Endotoxin: Less than 1 EU per ug by the LAL method.
Formulation: The recombinant SARS-CoV-2 Spike RBD-His-Avi was lyophilized from 0.22 um filtered solution in 20 mM PB (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.
Shipping: The product is shipped with ice packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.
The receptor binding domain (RBD) in the S1 subunit of the SARS-CoV-2 (2019-nCoV) spike (S) glycoprotein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of virus entry inhibitors, neutralizing antibodies, and vaccines. There are two subunits, S1 and S2, in the SARS-CoV-2 spike (S) glycoprotein. The S1 subunit, the N-terminal 14–685 amino acids of S protein, contains N-terminal domain (NTD), receptor binding domain (RBD, 331-524), and receptor binding motif (RBM). The SARS-CoV and SARS-CoV-2 S proteins mediate viral entry into host cells by binding to a host receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD), and then fusing the viral and host membranes through the S2 subunit. The ACE2-binding affinity of the Spike RBD of SARS-CoV-2 is 10- to 20-fold higher than that of SARS-CoV.
The RBD in the SARS-CoV-2 S protein has become a popular target of antibodies for diagnostics test and proteins and antibodies for therapeutic drugs. It is critical to use an active protein with natural conformation and post-translational modification as the antigen, even for the IgM/IgG test kit which is popularly used to check people already carrying immune response against the COVID-19 virus. Thus, the spike RBD protein should be expressed in mammalian cells, such as HEK 293 and CHO cells.
The amino-acid sequence identity is around 74% between the RBDs in the SARS-CoV and SARS-CoV-2 spike proteins, similar to the 77% identity between the whole spike proteins of SARS-CoV and SARS-CoV-2. Such a high degree of sequence similarity raises the possibility that cross-reactive epitopes may exist. Although the SARS-CoV RBD polyclonal antibodies can recognize both viruses, only one out of a few published RBD monoclonal antibodies neutralizing SARS-CoV binds to SARS-CoV-2 spike RBD. Out of the 28 residues in the epitope of the S1 RBD monoclonal antibody, only 4 residues (86%) in SARS-CoV-2 are different from SARS-CoV. However, the S1 RBD mAb binds to SARS-CoV spike RBD (Kd = 1 nM) with a much higher affinity than to SARS-CoV-2 spike RBD (Kd = 115 nM, or 6.3 nM measured by another lab).
Recombinant SARS-CoV-2 S RBD-His and RBD-Fc proteins are both available with an Avi site, which is for biotinylation. Biotinylated recombinant SARS-CoV-2 S RBD-His and RBD-Fc proteins as well as the S1 RBD monoclonal antiobdy are also available. Please ask for a quote if you need RBD mutants or a protein with different modification or components.
To check more Syd Labs SARS-CoV-2 (2019-nCoV) Antigen and Antibody Reagents and Discovery Services